Overview

SentoClone® Compared to Reference Treatment in Advanced Malignant Melanoma

Status:
Unknown status
Trial end date:
2011-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to elucidate whether SentoClone® gives improved treatment responses in patients with advanced malignant melanoma in comparison to established reference treatment(s).
Phase:
Phase 2
Details
Lead Sponsor:
SentoClone AB
Treatments:
Dacarbazine
Temozolomide